Foghorn Therapeutics Provides First Quarter 2024 Financial a

Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation...

Related Keywords

United States , Massachusetts , Cambridge , Cambridgeshire , United Kingdom , American , Peter Kelleher , Greg Dearborn , Adam Silverstein , Karin Hellsvik , Adrian Gottschalk , B Degrader Program , Key Recent Program Updates , American Association For Cancer Research , Exchange Commission , Linkedin , Twitter , Degrader Program , Therapeutics Inc , Nasdaq , Foghorn Therapeutics Inc , Development Expenses , Company Annual Report On Form , Gene Traffic Control , Chief Executive Officer , Cancer Research , Annual Meeting , Chromatin Regulation , Chromatin Regulation Summit , Kristian Humer , Chief Financial , Recent Program Updates , Kinase Inhibitor , Cancer Cell , Cash Equivalents , Gene Traffic , Annual Report , Consolidated Statements , Months Ended March , Foghorn Therapeutics , Lifesci Advisors , Markets ,